--- title: "BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 12 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295803416.md" datetime: "2026-08-13T13:02:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295803416.md) - [en](https://longbridge.com/en/news/295803416.md) - [zh-HK](https://longbridge.com/zh-HK/news/295803416.md) generator: "portal-rs" --- # BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 12 M Revenue: As of FY2026 Q2, the actual value is USD 12 M. EPS: As of FY2026 Q2, the actual value is USD -0.05. EBIT: As of FY2026 Q2, the actual value is USD -455 K. ### Second Quarter 2026 Financial Highlights (vs. Prior-Year Period) #### Net Product Revenue Net product revenue was $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period. #### Gross Margin Gross margin improved to 80% from 71%, an improvement of approximately 920 basis points. #### Net Loss Net loss decreased to - $0.6 million from - $5.3 million. #### Adjusted EBITDA Adjusted EBITDA improved to - $0.2 million from - $5.1 million, an improvement of approximately $5.0 million. #### Cost of Revenues Cost of revenues was $2.4 million, compared to $2.6 million in the prior-year period. #### Gross Profit Gross profit was $9.6 million, compared to $6.4 million in the second quarter of 2025. #### Selling, General and Administrative Expenses Selling, general and administrative expenses decreased by $0.9 million to $9.7 million, compared to $10.6 million in the prior-year quarter. #### Research and Development Expenses Research and development expenses were $0.4 million, compared to $0.9 million in the prior-year quarter. #### Loss from Operations Loss from operations was - $524 thousand, compared to - $5,079 thousand in the prior-year period. #### Total Operating Expenses Total operating expenses were $12,527 thousand, compared to $14,109 thousand in the prior-year period. ### First Half 2026 Financial Highlights (vs. Prior-Year Period) #### Net Product Revenue Net product revenue for the six months ended June 30, 2026, was $22.1 million, an increase of 25.4% from $17.6 million in the prior-year period. #### Gross Margin Gross margin improved to 80% from 67%. #### Net Loss Net loss decreased to - $5.4 million from - $9.5 million. #### Adjusted EBITDA Adjusted EBITDA improved to - $3.7 million from - $9.5 million. #### Cash Flow from Operating Activities Cash used in operating activities was - $1.7 million, compared to - $7.2 million in the prior-year period, representing a reduction of approximately 76%. #### Cost of Revenues Cost of revenues was $4.5 million, compared to $5.9 million in the prior-year period. #### Gross Profit Gross profit was $17.6 million, compared to $11.7 million in the prior-year period. #### Selling, General and Administrative Expenses Selling, general and administrative expenses increased by $1.4 million to $20.7 million, compared to $19.3 million in the prior-year period. #### Research and Development Expenses Research and Development expenses were $1.3 million, compared to $2.1 million in the prior-year period. #### Loss from Operations Loss from operations was - $4,844 thousand, compared to - $9,629 thousand in the prior-year period. #### Total Operating Expenses Total operating expenses were $26,931 thousand, compared to $27,246 thousand in the prior-year period. ### Balance Sheet Highlights (as of June 30, 2026, vs. December 31, 2025) #### Cash and Cash Equivalents Cash and cash equivalents were $4.7 million as of June 30, 2026, compared to $6.4 million as of December 31, 2025. #### Total Liabilities Total liabilities were $18.1 million as of June 30, 2026, essentially unchanged from $18.1 million at December 31, 2025. #### Outstanding Indebtedness Outstanding indebtedness consisted of $4.6 million of convertible notes, net, maturing in November 2027. #### Total Stockholders’ Equity Total stockholders’ equity was $6.0 million as of June 30, 2026, compared to $10.5 million at December 31, 2025. ### Outlook / Guidance Biofrontera Inc. expects to launch Ameluz for superficial basal cell carcinoma (sBCC) in Q1 2027, following a PDUFA date in late September of this year. If approved, Ameluz would be the first PDT in the U.S. for cancerous tumors, supported by positive Phase III results for actinic keratoses and Phase 2B data in acne. The company continues to progress towards achieving cash flow breakeven in 2026, and the ITC order affecting its RhodoLED XL lamp is not expected to impact full-year 2026 revenue goals. ### Related Stocks - [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md) ## Related News & Research - [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md) - [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md) - [1-800 FLOWERS.COM Q4 2026 Earnings Preview](https://longbridge.com/en/news/298470090.md) - [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md) - [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**